BRAIN CANCER

General Cancer

The first patient has been dosed in a phase I/II open-label, multicenter trial investigating a novel immunotherapy combination in patients with newly diagnosed glioblastoma. Fifty patients have been accrued in the trial, as of May 31, 2018, which will be conducted at 25 sites across the nation.

W. K. Alfred Yung, MD, a professor of Neuro-oncology at MD Anderson Cancer Center, discusses the future of immuno-oncology in the treatment landscape of brain cancer. 

Regorafenib (Stivarga) improved overall survival and progression-free survival compared with lomustine (Gleostine) for patients with glioblastoma that recurred following surgery and treatment with the Stupp regimen, according to updated results presented in a poster at the 2018 ASCO Annual Meeting.

Daniela A. Bota, MD, medical director of Neuro-Oncology at University of California Irvine, discusses the findings from a dose-escalation trial of marizomib.

The anticancer immunotherapy vaccine SL-701, when used with immunostimulants, induced antitumor activity in patients with relapsed/refractory glioblastoma both alone and in combination with bevacizumab, according to updated phase II results from the 2-stage STML-701-0114 trial presented at the 2018 ASCO Annual Meeting.

According to phase I findings recently published in the<em> New England Journal of Medicine,&nbsp;</em>^&nbsp;the&nbsp;recombinant oncolytic poliovirus PVSRIPO demonstrated&nbsp;a 2- and 3-year overall survival (OS) rate of 21% (95% CI, 11%-33%) for patients with recurrent grade IV malignant glioblastoma.